Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with prostate cancer whose PSA levels are rising after both surgical removal of the prostate and radiotherapy, with PSA levels doubling within 12 months or less.
- People who have not had hormone therapy in the past 12 months, or whose testosterone levels have returned to normal levels.
- People whose PSMA PET scan showed no signs of cancer returning in the local area where the prostate was removed (distant spread to other parts of the body is allowed).
- People who are generally well enough to carry out daily activities with little to no limitation (confirm with trial site).
- People with healthy enough blood counts — including white blood cells, platelets, and haemoglobin — as measured by recent blood tests.
- People with adequately functioning kidneys and normal albumin (a protein in the blood) levels, as measured by blood tests.
- People who are able to read, understand, and sign a consent form agreeing to take part in the trial.
Who may not be able to join:
- People who are currently taking part in another clinical trial involving a medical treatment or intervention.
- People with serious cancer-related or other medical conditions where life expectancy is not expected to be longer than one year.
- People with significant physical or mental health conditions that could interfere with the trial's goals or assessments.
- People experiencing a complete blockage of urinary flow, or severe urinary incontinence that cannot be managed.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 004314040058742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
PSA response; Emergence of therapy toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.